Recruiting

qOBM

Sponsor:

Emory University

Code:

NCT07213154

Conditions

Malignant Skin Neoplasm

Skin Disorder

Skin Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Quantitative Oblique Back-Illumination Microscopy

Radiation Therapy

Study Details

Brief summary:

This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.

Conditions

Malignant Skin Neoplasm

Skin Disorder

Skin Neoplasm

Study ID

NCT07213154

Start date

Oct 15, 2025

Status verified date

Dec, 2025

Completion date

Sep 17, 2027

Anticipated

Primary completion date

Sep 17, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or Female
  • Candidate with skin lesions
  • Signed study-specific informed consent prior to study entry
  • ≥ 18 years old

Exclusion Criteria:

  • Prior surgery or radiotherapy to the area to be treated

Study Design

Enrollment

10 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Group I (qOBM)

Patients who have skin melanoma and/or suspected dysplastic nevi undergo qOBM optical imaging scan on study. Patients may undergo 2 additional qOBM optical imaging scans at the discretion of the treating physician. After qOBM scans, patients who are diagnosed with skin cancer may proceed to Group II.

experimental: Group II (qOBM, SOC RT)

GROUP II: Patients with skin cancer who are undergoing SOC RT undergo qOBM optical imaging scans prior to- and during or after SOC RT on study. Patients may also undergo qOBM optical imaging scans additional at approximately 1, 6, and 12 months after completion of SOC RT at the discretion of the treating physician.

Interventions

Quantitative Oblique Back-Illumination Microscopy

Undergo qOBM

Radiation Therapy

Undergo SOC RT

Primary outcome measure

  • qOBM Clinical Assessment [ Time Frame: Up to 12 months ]

Central Contacts and Locations

Central contacts

Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR

404-778-3473m.k.khan@emory.edu

Locations

Emory University Hospital Midtown

Recruiting

Atlanta, Georgia, United States, 30308

Contacts

Tiffaney Roundtree

tiffaney.laquinta.roundtree@emory.edu

Principal Investigator:

Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR

Emory University Hospital/Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Tiffaney K. Roundtree

tiffaney.laquinta.roundtree@emory.edu

Principal Investigator:

Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR

More Information

Sponsor

Emory University

Last update posted

Dec 16, 2025

Last verified

Dec, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Emory University on 2025-12-16.